TOPページ
|
英語
日本語
|
CONNECT WITH US:
ホーム
JCNについて
サービス
お問い合わせ
会員企業ログイン
*
ホーム
プレスリリース一覧
China Medical System Holdings Ltd.
プレスリリース一覧
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10
Jan 24, 2025 23:00 JST
More info..
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 09, 2025 09:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type.
More info..
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 09, 2024 14:00 JST
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
More info..
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
Dec 02, 2024 22:30 JST
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
More info..
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Sep 24, 2024 22:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 16, 2024 14:00 JST
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
Aug 05, 2024 23:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00 JST
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development.
More info..
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Jun 25, 2024 21:46 JST
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
Jun 18, 2024 19:53 JST
More info..
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06 JST
More info..
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Apr 01, 2024 21:30 JST
More info..
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 11:29 JST
More info..
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Feb 04, 2024 10:00 JST
More info..
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Jan 02, 2024 15:00 JST
More info..
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Dec 13, 2023 18:36 JST
More info..
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Aug 24, 2023 21:00 JST
More info..
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST
More info..
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST
More info..
1
新着プレスリリース
New Database of Materials Accelerates Electronics Innovation
2025年05月02日 23時00分
現実世界での探検を通じ、人々をつなぐ―Jagat宝探しイベント、日本初上陸
2025年05月02日 15時00分
Open Dialogue 'Future of the World. New Platform for Global Growth' Launches at Russia National Centre
2025年04月29日 16時00分
オープンダイアログ「世界の未来。グローバル成長の新たなプラットフォーム」がロシア国立センターで開催
2025年04月29日 14時00分
富士通、光ネットワークの発展に貢献したデジタルコヒーレント光受信技術により、令和7年春の褒章において紫綬褒章を受章
2025年04月28日 11時00分
米国株式アクティブ残高9年連続世界No.1ティー・ロウ・プライス[1] R&Iファンド大賞2025最優秀ファンド賞を受賞
2025年04月25日 15時15分
Honda、2025年3月度 四輪車 生産・販売・輸出実績を発表
2025年04月24日 15時15分
トヨタ、米国ウェストバージニア工場に8,800万ドルを追加投資
2025年04月24日 14時30分
トヨタ、2024年度 販売・生産・輸出実績を発表
2025年04月24日 13時35分
アリックスパートナーズ、中国自動車市場の最新調査を発表
2025年04月23日 13時00分
New Trading Bot Pivozon Targets Gold Traders Using Hourly Chart Strategies
2025年04月22日 16時00分
Meerkat ($MERK) introduces utility-focused meme ecosystem with staking, gaming, and AI features
2025年04月22日 12時00分
富士通と理研、世界最大級の256量子ビットの超伝導量子コンピュータを開発
2025年04月22日 11時00分
PerfectSwell(R) Zion、建設開始へ
2025年04月22日 10時00分
Dubai Sees Launch of Litepips as Avenix Fzco Brings AI to Commodity Trading
2025年04月20日 16時00分
FXSpire Debuts in Dubai as Forex Traders Seek Smarter Tools Amid Global Uncertainty
2025年04月18日 22時00分
FXiBot Launches with a Precision Strategy for GBP/USD Trading
2025年04月18日 21時00分
JERA Cross とのぞみエナジーとの特定卸供給に関する基本契約締結とHourly Matching による電力供給の開始について
2025年04月17日 15時00分
Fiskl and Airwallex Transform SME Finance with AI
2025年04月17日 14時00分
MHIEC、東京都下水道局から汚泥焼却設備再構築工事を受注
2025年04月17日 11時30分
もっと見る >>